## **Claims**

## 1. A composition comprising:

- a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition during a period of at least about one month at a rate sufficient to induce and maintain chemical castration of a male patient, and
- 10 a sustained release formulation of an estrogenic composition capable of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient.

15

2. The composition according to claim 1, wherein the sustained release formulation of a gonadotropin hormone releasing hormone composition is capable of releasing the gonadotropin hormone releasing hormone composition at a rate between about 10 and about 1,000 µg per day.

20

25

3. The composition according to claim 1, wherein the sustained release formulation releases an estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100  $\mu g$  of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the daily release of the estrogenic composition occurring during said second phase.

## 4. A composition comprising:

a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 µg per day and a sustained release formulation of an estrogenic composition capable of

WO 2004/096259 PCT/IB2004/001334

5

20

25

30

- 23 -

releasing the estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100  $\mu g$  of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase.

- 5. The composition according to any of the preceding claims, wherein the gonadotropin hormone releasing hormone composition is selected from the group consisting of gonadotropin hormone releasing hormone, agonists of gonadotropin hormone releasing hormone, antagonists of gonadotropin hormone releasing hormone and mixtures thereof.
- 6. A composition as in claims 1, 2, 3 or 4, wherein the gonadotropin hormone releasing hormone composition is a gonadotropin hormone releasing hormone agonist selected from the group consisting of leuprorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histerelin, gonadorelin, and salts and mixtures thereof.
  - 7. A composition as in claims 1, 2, 3 or 4, wherein the estrogenic composition is selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, diethylstilbestrol dipropionate, diethylstilbestrol monobenzyl ether, equilelinin, equilelinin sulfate, estetrol, estradiol,  $(3\alpha,17\beta)$ -estr-4-ene-3,17-diol, estriol, hemisuccinate, estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.
  - 8. A composition as in claims 1, 2, 3 or 4, wherein the gonadotropin releasing hormone composition is triptorelin or a salt thereof and the estrogenic composition is estradiol.

WO 2004/096259 PCT/IB2004/001334

- 24 -

9. The composition of claim 8, wherein triptorelin, or a triptorelin salt, is released at a rate of about 100 µg per day and estradiol is released at a rate between about 25 and 50 µg per day.

5

10

15

20

25

30

Administering to a patient suffering from prostate cancer a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at a rate sufficient to induce and maintain chemical castration of the patient, and Simultaneously administering to the patient a sustained release formulation of an estrogenic composition capable of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient.

11. A method for the treatment of prostate cancer comprising:

Administering to a patient suffering from prostate cancer a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 μg per day, and Simultaneously administering to the patient a sustained release formulation of an estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100 μg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase.

A method for the treatment of prostate cancer comprising:
Administering to a patient suffering from prostate cancer a sustained

WO 2004/096259 PCT/IB2004/001334

release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 µg per day, and

- 25 -

- Simultaneously administering to the patient a sustained release formulation of an estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100 μg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase.
- 13. A method as in claims 10, 11 or 12, wherein the gonadotropin hormone releasing hormone composition is selected from the group consisting of gonadotropin hormone releasing hormone, agonists of gonadotropin hormone releasing hormone, antagonists of gonadotropin hormone releasing hormone and mixtures thereof.
- 14. A method as in claims 10, 11 or 12, wherein the gonadotropin hormone releasing hormone composition is a gonadotropin hormone releasing hormone agonist selected from the group consisting leuprorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histerelin, gonadorelin, and salts and mixtures thereof.

25

30

15. A method as in claims 10, 11 or 12, wherein the estrogenic composition is selected from the group consisting of chlorotrianisene, dienestrol, dienestrol, diethylstilbestrol dipropionate, diethylstilbestrol monobenzyl ether, equilelinin, equilelinin sulfate, estetrol, estradiol,  $(3\alpha,17\beta)$ -estr-4-ene-3,17-diol, estriol, hemisuccinate, estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

16. A method as in claims 10, 11 or 12, wherein the gonadotropin releasing hormone composition is triptorelin or a salt thereof and the estrogenic composition is estradiol.

5

- 17. A method according to claim 16, wherein triptorelin, or a triptorelin salt, is released at a rate of about 100  $\mu$ g per day and estradiol is released at a rate between about 25 and 50  $\mu$ g per day.
- 18. A method as in claims 10, 11 or 12, wherein the composition is administered by a subcutaneous, intramuscular, or transdermal route.